The FDA has approved pretomanid tablets (TB Alliance) in combination with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
The FDA has approved Sirturo (bedaquiline; Janssen) for use in pediatric patients aged 12 to less than 18 years in MDR-TB.
An association has been identified between newly diagnosed active tuberculosis, diabetes, and body mass index.
The CDC has issued 3 recommendations for mitigating a reduction in tuberculosis testing capability.
In a review update, XpertMTB/RIF was found to be sensitive and specific for diagnosing pulmonary TB and rifampicin resistance which is consistent with the last review completed in 2014.
The novel Fujifilm SILVAMP TB LAM assay offers superior diagnostic sensitivity while also maintaining specificity, compared with standard assay.
In patients who are immunocompromised, such as people living with HIV, the new fourth-generation QuantiFERON-TB Gold Plus assay demonstrated similar sensitivity to the third-generation interferon-gamma release assay for the diagnosis of latent tuberculosis.
The CDC announced an expected 3 to 10 month shortage of Aplisol used as an aid in the diagnosis of tuberculosis.
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.
Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
